Pfizer to acquire Reviral as RSV race continues
The proposed USD 525m acquisition includes therapeutic candidates within the RSV indication, which Bavarian Nordic is also targeting.
Pharmaceutical giant Pfizer is continuing to expand its efforts within the RSV indication, fresh off success with its Covid-19 vaccine.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Bavarian Nordic could be first on the RSV market in China
For subscribers
